Photo from clinicaltrialsarena.com
Aug 7, 2024, 11:11
Earle Burgess: Important information for those who use enfortumab vedotin in practice
Earle Burgess, Genitourinary Medical Oncologist at Atrium Health Levine Cancer, shared on LinkedIn:
“Key question for the use of enfortumab vedotin (Padcev) in patients with advanced urothelial (bladder) cancer:
If I have to reduce the dose for side effects in someone who is responding to the drug, will it compromise the tumor response? Probably not.
That’s what was observed in the phase 3 trial that led to the initial approval of the drug based on analysis reported at ASCO24 (Abstract 4503). Important information for those who use this drug in practice.”
Source: Earle Burgess/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 15, 2024, 21:37
Nov 15, 2024, 21:26
Nov 15, 2024, 21:09
Nov 15, 2024, 21:05
Nov 15, 2024, 21:03
Nov 15, 2024, 21:02
Nov 15, 2024, 20:28
Nov 15, 2024, 19:31
Nov 15, 2024, 17:47
Nov 15, 2024, 17:45